Karyopharm Therapeutics: Karyopharm to Report Fourth Quarter and Full Year 2024 Financial Results on February 19, 2025

-- Conference Call Scheduled for Wednesday, February 19, 2025 , at 8:00 a.m. ET -- NEWTON, Mass. , Feb. 12, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it will report fourth quarter and full year 2024 financial results on Wednesday, February 19, 2025 . Karyopharm's management team will host a conference call and audio webcast at 8:00 a.m. ET on Wednesday, February 19, 2025 , to discuss the financial results and other company updates. To access the conference call, please dial (800) 836-8184 (local) or (646) 357-8785 (international) at least 10 minutes prior to the start time and ask to be joined into the Karyopharm Therapeutics call. A live audio webcast of the call, along with accompanying slides, will be available under "Events & Presentations" in the Investor section of the Company's website, http://investors.karyopharm.com/events-presentations . An archived webcast will be available on the Company's website approximately two hours after the event. About Karyopharm Therapeutics Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company whose dedication to pioneering novel cancer therapies is fueled by a belief in the extraordinary strength and courage of patients with cancer. Since its founding, Karyopharm has been an industry leader in oral compounds that address nuclear export dysregulation, a fundamental mechanism of oncogenesis. Karyopharm's lead compound and first-in-class, oral exportin 1 (XPO1) inhibitor, XPOVIO ® (selinexor), is approved in the U.S. and marketed by the Company in three oncology indications. It has also received regulatory approvals in various indications in a growing number of ex-U.S. territories and countries, including Europe and the United Kingdom (as NEXPOVIO ® ) and China . Karyopharm has a focused pipeline targeting indications in multiple high unmet need cancers, including in multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL). For more information about our people, science and pipeline, please visit www.karyopharm.com , and follow us on LinkedIn and on X at @Karyopharm. XPOVIO ® and NEXPOVIO ® are registered trademarks of Karyopharm Therapeutics Inc. View original content to download multimedia: https://www.prnewswire.com/news-releases/karyopharm-to-report-fourth-quarter-and-full-year-2024-financial-results-on-february-19-2025-302372912.html SOURCE Karyopharm Therapeutics Inc.